Showing 3201-3210 of 3543 results for "".
- Foamix Pharmaceuticals Ltd. Closes Its $69 Million Public Offering of Ordinary Shareshttps://practicaldermatology.com/news/foamix-pharmaceuticals-ltd-closes-its-69-million-public-offering-of-ordinary-shares/2458956/Foamix Pharmaceuticals Ltd. closed its follow-on public offering. A total of 7,419,353 ordinary shares were sold at a price to the public of $9.30 per share. Prior to closing, the underwriters fully exercised their option to purchase 967,741 additional ordinary shares. The net proceeds from the s
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- Provectus Biopharmaceuticals, Pfizer Receive Patent Allowance for Use of PV-10 in Combination with Systemic Immunotherapy Agents in Treatment of Cancerhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-pfizer-receive-patent-allowance-for-use-of-pv-10-in-combination-with-systemic-immunotherapy-agents-in-treatment-of-cancer/2458962/Provectus Biopharmaceuticals, Inc., a clinical-stage oncology and dermatology biopharmaceutical company, announced today that it has received from the US Patent and Trademark Office a N
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Cipher Pharmaceuticals Acquires Innocutishttps://practicaldermatology.com/news/cipher-pharmaceuticals-acquires-innocutis/2458969/Cipher Pharmaceuticals Inc. has acquired Innocutis Holdings LLC, a privately held specialty dermatology company, for US$45.5 million in cash. (All financial references are in U.S. dollars unless otherwise noted.) "This acquisition marks our commercial entry to the U.S. market an
- FixMySkin Unveils New Lookhttps://practicaldermatology.com/news/fixmyskin-unveils-new-look/2458974/FixMySkin Healing Balms with 1% Hydrocortisone have a new look with the same great formula. Now available in environmentally friendly packaging, these balms come in two convenient sizes for the lips and body. Th
- Novan Secures $50 Million Private Financinghttps://practicaldermatology.com/news/novan-secures-50-million-private-financing/2458973/Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that it has secured $50 million in an oversubscribed private financing. New investor Malin Corporation Plc. (MLC: ISE) functioned as the cornerston
- New Officers Assume Roles with the American Academy of Dermatologyhttps://practicaldermatology.com/news/new-officers-assume-roles-with-the-american-academy-of-dermatology/2458976/Mark Lebwohl, MD, FAAD, a dermatologist in New York City, took office as president of the American Academy of Dermatology (AAD). Timothy G. Berger, MD, FAAD, a dermatologist in San Francisco, also assumed his position as vice president of the AAD. Drs. Lebwohl and Berger assumed office at the con
- NeoStrata® Launches SKIN ACTIVE Dermal Replenishmenthttps://practicaldermatology.com/news/neostrata-launches-skin-active-dermal-replenishment/2458980/NeoStrata Company, Inc., today announced the launch of SKIN ACTIVE Dermal Replenishment, an intense hydrator that delivers a powerful four-pronged anti-aging approach. Created to synergistically replenish optimal hydration levels and reverse signs of a
- NuGene BioPharma, Inc. Acquires SkinGuardian®https://practicaldermatology.com/news/nugene-biopharma-inc-acquires-skinguardian/2458986/NuGene International, Inc.’s subsidiary corporation, NuGene BioPharma, Inc., has acquired all rights, title and interest in and to SkinGuardian®, an FDA-approved (monographed) skin protectant, antiseptic, and moisturizing topical cream. NuGene BioPharma acquired all intellectual